natgillin/translations-raw huggingface dataset:
Diclofenac sodium DOLOTREN supositorios 
Spain natrijev diklofenakat DOLOTREN ampollas
Diclofenac sodium Diclofenacratiopharm 
Diclofenacratiopharm svečka rektalna uporaba
Diclofenac sodium DICLOFENAC SANDOZ 50 MG 
Austria natrijev diklofenakat Diclofenac Sandoz 50 mg
Diclofenacum natricum Diclofenac 50 mg suppositories 
Latvia natrijev diklofenakat Diclofenac 50 mg suppositories svečka rektalna uporaba
Diclofenac sodium Diclofenac Genericon 75 mg - Ampullen 
Austria natrijev diklofenakat Diclofenac Genericon 75 mgAmpullen
Diclofenac sodium Diclofenacnatrium Apotex 25 mg, zetpillen 
The Netherlands natrijev diklofenakat Diclofenacnatrium Apotex 25 mg, zetpillen svečka rektalna uporaba
DICLAC ID 150 MG 150mg 
DICLAC ID 150 MG 150mg tableta s prirejenim sproščanjem
Diclofenac sodium Diclofenacnatrium 50 mg, maagsapresistente tabletten 
United Kingdom natrijev diklofenakat Diclofenacnatrium 50 mg, maagsapresistente tabletten
Diclofenac potassium Diklotab 
Poland natrijev diklofenakat Difadol
VOLTAREN 100 mg retard filmtabletta 
VOLTAREN 100 mg retard filmtabletta prolonged-release filmsko obložena tableta
Diclofenac potassium Diclobene rapid 50 mg Filmtabletten 
Diclomex Rapid 50mg filmsko obložena tableta
Diclofenac sodium Diclofenacnatrium 25 mg, maagsapresistente tabletten 
United Kingdom natrijev diklofenakat Diclofenacnatrium 25 mg, maagsapresistente tabletten
Diclofenac sodium Effekton 100mg Zäpfchen 
Italy natrijev diklofenakat Effekton 100mg Zäpfchen svečka rektalna uporaba
Diclofenacum natricum Olfen 100 SR 
2740-298 Porto Salvo Portugal natrijev diklofenakat Olfen 100 SR
Diclofenacum natricum Naklofen SR 100 mg prolonged-release tablets 
Germany natrijev diklofenakat Voltaren Retard-100 100mg tableta s podaljšanim sproščanjem
Diclofenac potassium Diklok 
Belgium kalijev diklofenakat
Diclofenac sodium Diclofenac Natrium HERMES 25 mg 
82049 Großhesselohe Germany natrijev diklofenakat Diclofenac Natrium HERMES 25 mg
Diclofenac sodium DICLOFENAC "S.Med" 50 mg 
1220 Vienna Austria natrijev diklofenakat DICLOFENAC "S.Med" 50 mg
Diclofenac sodium Diclofenac G.L. 
A-8502 Lannach Austria natrijev diklofenakat Diclofenac G.L.
Belgium SOCOBOM N.V. Louizalaan 149 box 24 
Luksemburg Socobom S.A Avenue Louise 149 b24 B-1050 Bruxelles Belgium natrijev diklofenakat Polyflam-75
The Netherlands Novartis Consumer Health B.V. Claudius Prinselaan 142 
Nizozemska Novartis Consumer Health B.V.
Diclofenac sodium DICLOFENAC BIOGARAN 50 mg, comprimé pelliculé gastrorésistant 
92700 Colombes France natrijev diklofenakat DICLOFENAC BIOGARAN 50 mg, comprimé pelliculé gastrorésistant filmsko obložena gastrorezistentna tableta
Diclofenac sodium Almiral 25mg tablets 25mg 
Cyprus natrijev diklofenakat Almiral 25mg tablets
Diclofenac sodium VOLTAREN RETARD 100 mg comprimidos de liberación modificada 
08013 Barcelona Spain natrijev diklofenakat VOLTAREN RETARD 100 mg comprimidos de liberación modificada tableta s prirejenim sproščanjem
Diclofenac sodium Diclofenacnatrium Actavis 50 mg, maagsapresistente tabletten 
The Netherlands natrijev diklofenakat Diclofenacnatrium Actavis 50 mg, maagsapresistente tabletten
Diclofenac sodium Diclofenacnatrium Apotex 50 mg, zetpillen 
The Netherlands natrijev diklofenakat Diclofenacnatrium Apotex 50 mg, zetpillen svečka rektalna uporaba
Diclofenac sodium Diclofenacnatrium Sandoz 50, maagsapresistente tabletten 50 mg 
1327 AH Almere The Netherlands natrijev diklofenakat Diclofenacnatrium Sandoz 50, maagsapresistente tabletten 50 mg
DICLAC ID 75 MG 75mg 
DICLAC ID 75 MG 75mg tableta s prirejenim sproščanjem
Diclofenacum natricum APO-DICLO 25 MG 25mg 
2333 CR Leiden The Netherlands natrijev diklofenakat APO-DICLO 25 MG 25mg
25mg/ml solution for injection 
25mg/ml raztopina za injiciranje intramuskularna uporaba
Diclofenac sodium FLEFARMIN 
Greece natrijev diklofenakat FLEFARMIN
Diclofenacum natricum Diclofenac GSK 
Italy natrijev diklofenakat DICLOFENAC GERMED
Film-coated tablet Oral use 
Cataflam obložena tableta peroralna uporaba
Diclofenac sodium Diclofenacnatrium Actavis 100 mg, zetpillen 
The Netherlands natrijev diklofenakat Diclofenacnatrium Actavis 100 mg, zetpillen svečka rektalna uporaba
Masate, Milano - 20060 Italy 
Masate, Milano - 20060 Italy natrijev diklofenakat NATRIJEV DIKLOFENAKAT BIL
Diclofenac sodium Diclofenacratiopharm 25 mg magensaftresistente Tabletten ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany 
Latvija ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany natrijev diklofenakat Diclofenacratiopharm 25 mg gastro-resistant tablets
Diclofenac sodium Diclofenac Na Pharmacin 100 mg, tabletten met gereguleerde afgifte 
3335 LH Zwijndrecht The Netherlands natrijev diklofenakat Diclofenac Na Pharmacin 100 mg, tabletten met gereguleerde afgifte tableta s prirejenim sproščanjem
Prolonged-release film-coated tablet 
Diklotab filmsko obložena tableta
Diclofenac sodium Diclofenacratiopharm 50 mg magensaftresistente Tabletten ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany 
Latvija ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany natrijev diklofenakat Diclofenacratiopharm 50 mg gastro-resistant tablets
LABORATORIOS NORMON, S.A. Ronda de Valdecarrizo, 6 28760 Tres Cantos (Madrid) Spain 
Ronda de Valdecarrizo, 6 28760 Tres Cantos (Madrid) Spain natrijev diklofenakat DICLOFENACO NORMON 50 mg comprimidos dispersables EFG
DICLOFENAC AL 50 mg végbélkúp 
DICLOFENAC AL 50 mg végbélkúp svečka rektalna uporaba
Diclofenacum natricum VERAL 75 
53003 Pardubice Czech Republic natrijev diklofenakat VERAL 75
ARTHROTEC FORTE 75mg 0.2mg 
ARTHROTEC FORTE 75mg 0,2mg filmsko obložena tableta
12,5mg Film-coated tablet Oral use 
12,5mg obložena tableta peroralna uporaba
Diclofenac sodium Diclofenacnatrium Actavis 25 mg, maagsapresistente tabletten 
The Netherlands natrijev diklofenakat Diclofenacnatrium Actavis 25 mg, maagsapresistente tabletten
Diclofenac sodium Dignofenac 25mg 25mg 
71034 Böblingen Germany natrijev diklofenakat Dignofenac 25mg 25mg
Diclofenac potassium Dicuno 25 mg filmcoated tablets 
Diclofenac potassium 25mg Tablets filmsko obložena tableta
Brausetabletten 
zrnca
Diclofenac sodium Diclofenacnatrium Actavis 50 mg, zetpillen 
The Netherlands natrijev diklofenakat Diclofenacnatrium Actavis 50 mg, zetpillen svečka rektalna uporaba
Diclofenac sodium Diclofenac Natrium HERMES 50 mg 
82049 Großhesselohe Germany natrijev diklofenakat Diclofenac Natrium HERMES 50 mg
The Netherlands Pharmacin B.V. Molenvliet 103 
Nizozemska Pharmacin B.V.
Diclofenac sodium Diclofenac Na zetpil CF 100 mg, zetpillen 
Poland natrijev diklofenakat Diclofenac GSK 100mg svečka rektalna uporaba
LABORATORIOS LLORENS, S.A. Ciudad de Balaguer, 7-11 08022 Barcelona Spain 
Ciudad de Balaguer, 7-11 08022 Barcelona Spain natrijev diklofenakat DICLOFENACO LLORENS 100 mg supositorios EFG
Diclofenac sodium Diclofenac 1A Pharma retard 150 mg - Tabletten 
1A Pharma GmbH Stella-Klein-Löw-Weg 17 1020 Vienna Austria natrijev diklofenakat Diclofenac 1A Pharma retard 150 mg - Tabletten tableta s podaljšanim sproščanjem
Diclofenac Lidocaine 
Germany kalijev diklofenakat
Diclofenacum natricum Diclac 100 mg modified release tablets 
Verovskova 57 SI-1000 Ljubljana Slovenia natrijev diklofenakat Diclac 100 mg modified release tablets tableta s prirejenim sproščanjem
Diclofenac sodium Antigen Diclofenac Sodium Injection 
Italy natrijev diklofenakat DICLOFENAC ANGENERICO
Diclofenac potassium Voltaren Akti 25 mg soft capsules 
Voltaren Rapid 25 mg kapsula, mehka peroralna uporaba
OLFEN DEPOCAPS 75mg 
OLFEN DEPOCAPS 75mg tableta s podaljšanim sproščanjem
Diclofenac sodium DIFEND 
Italy natrijev diklofenakat DEFLAMAT
Diclofenac sodium Diclofenacnatrium Actavis 25 mg, zetpillen 
The Netherlands natrijev diklofenakat Diclofenacnatrium Actavis 25 mg, zetpillen svečka rektalna uporaba
Diclofenac sodium POLYFLAM EX RUFIMAX EX 
Louizalaan 149 box 24 1050 Ixelles Belgium natrijev diklofenakat POLYFLAM EX RUFIMAX EX
Diclofenac sodium Diclac 75 mg Prolonged -Release 
Rowex Ltd Bantry, Co. Cork Ireland natrijev diklofenakat Diclac 75 mg Prolonged -Release
Diclofenacum natricum OLFEN-100 SR 
2740-298 Porto Salvo Portugal natrijev diklofenakat OLFEN-100 SR
Diclofenacum natricum Dicloberl 100 mg suppositories 
Ireland natrijev diklofenakat Difene 100mg Suppositories svečka rektalna uporaba
Croydon, Surrey CR0 0XT United Kingdom 
12-16 Addiscombe Road Croydon, Surrey CR0 0XT United Kingdom natrijev diklofenakat Mercury Pharms Econac SR
Diklofenak "Orifarm" 25mg 
Diklofenak "Orifarm"
86156 Augsburg Germany 
86156 Augsburg Germany natrijev diklofenakat Diclofenbeta 25 25mg
Diclofenacum natricum Diclomelan retard 100 mg sustainedrelease tablets 
Germany natrijev diklofenakat Diclo KD retard 100mg tableta s podaljšanim sproščanjem
Diclofenac sodium DOLO-VOLTAREN 50 mg comprimidos dispersables 
08013 Barcelona Spain natrijev diklofenakat DOLO-VOLTAREN 50 mg comprimidos dispersables orodisperzibilna tableta
DICLOREUM 100 mg 100mg 
DICLOREUM 100 mg 100mg svečka rektalna uporaba
Tratul 50 mgKapseln 
Tratul 50 mgKapseln gastrorezistentna kapsula, mehka
Diclofenacum kalium Voltaren Rapid 
Voltaren Rapid obložena tableta peroralna uporaba
Latvia ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany 
Slovaška ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany
Diclofenac sodium Diclo-CT 75mg/2ml Ampullen 
Germany natrijev diklofenakat Diclo-CT 75mg/2ml Ampullen raztopina za injiciranje intramuskularna uporaba
Diclofenac potassium Diclofenac T ratiopharm 
The Netherlands natrijev diklofenakat Diclofenac Na ratiopharm retard
Diclofenac sodium VURDON 
Italy kalijev diklofenakat
Diclofenac sodium Diclofenac Na zetpil CF 50 mg, zetpillen 
Poland natrijev diklofenakat Diclofenac GSK 50mg svečka rektalna uporaba
Diclofenac sodium Diclofenac 100 Heumann Supp. 
90449 Nürnberg Germany natrijev diklofenakat Diclofenac 100 Heumann Supp.
Film-coated sustained release tablet 
filmsko obložena tableta s podaljšanim sproščanjem
Diclofenacum kalium Diclofenac Rapid Orifarm 
Diclofenac Rapid Orifarm filmsko obložena tableta
VERAL 100 retard 100mg 
VERAL 100 mg 100mg svečka rektalna uporaba
Box 51166 3502 Lemesos Cyprus 
P.O. Box 51706 Lemesos Cyprus natrijev diklofenakat REMETHAN SUSTAINED
Prolonged-release tablet 
Retardtabletten tableta s podaljšanim sproščanjem
Diclofenac sodium Mercury Pharms Diclofenac Sodium 
12-16 Addiscombe Road Croydon, Surrey CR0 0XT United Kingdom natrijev diklofenakat Mercury Pharms Diclofenac Sodium
Diclofenac sodium Diclofenbeta 25 25mg betapharm Arzneimittel GmbH Kobelweg 95 
Belgium natrijev diklofenakat Diclofenac EG-25 25mg obložena tableta peroralna uporaba
Estonia ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany 
Estonija ratiopharm GmbH Graf Arco Strasse 3 D-89079 Ulm Germany dikofenak
Modified-Release Capsule, Hard 
kapsula s prirejenim sproščanjem, trda
Diclofenac sodium Diclo KD 75 akut 
Germany natrijev diklofenakat Diclo KD 75 akut kapsula s prirejenim sproščanjem, trda
Diclofenac sodium Diclofenac 50 Heumann 
90449 Nürnberg Germany natrijev diklofenakat Diclofenac 50 Heumann
Diclofenac sodium Voltaren 100 mg Zäpfchen 
DICLOFENAC SODIC 100 mg svečka rektalna uporaba
Diclofenac potassium Diclofen Kalium KPC 25 mg Filmtabletten 
Diclofen Kalium KPC 25 mg Filmtabletten filmsko obložena tableta
Diclofenac sodium Tratul retard 100 mg - Filmtabletten 
A-1160 Vienna Austria natrijev diklofenakat Tratul retard 100 mg - Filmtabletten filmsko obložena tableta
12 February 2013 
12. februar 2013
The Committee appointed Ms H. Jukes as rapporteur and Mr G. J. Schefferlie as co-rapporteur. 
Odbor je za poročevalko imenoval H. Jukes, za soporočevalca pa G. J. Schefferlieja.
The final opinion was converted into a Decision by the European Commission on 12 February 2013. 
Končno mnenje je bilo dne 12. februarja 2013 spremenjeno v sklep Evropske komisije.
The decentralised procedure (NL/V/0164/003/DC) started on 17 June 2011. 
Decentralizirani postopek (NL/V/0164/003/DC) se je začel 17. junija 2011.
The application was submitted to the Netherlands as reference Member State and Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Italy, Poland, Spain and the United Kingdom as concerned Member States. 
Vloga je bila predložena Nizozemski kot referenčni državi članici ter Avstriji, Belgiji, Češki republiki, Danski, Franciji, Nemčiji, Madžarski, Irski, Italiji, Poljski, Španiji in Združenem kraljestvu kot zadevnim državam članicam.
The referral procedure started on 11 July 2012. 
Napotitveni postopek se je začel 11. julija 2012.
International non-proprietary name (INN): meloxicam 
Mednarodno nelastniško ime (INN): meloksikam
Written explanations were provided by the applicant on 11 September 2012. 
Predlagatelj je pisna pojasnila predložil 11. septembra 2012.
Veterinary Medicines and Product Data Management 
Zdravila za uporabo v veterinarski medicini in upravljanje podatkov o zdravilih
Meloxicam is a Non-Steroidal Anti-Inflammatory Drug. 
Meloksikam je nesteroidno protivnetno zdravilo.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amendments to the Summary of Product Characteristics, labelling and package leaflet in the Annex III. 
Seznam zadevnih imen zdravila je na voljo v Prilogi I. Znanstveni zaključki so podani v Prilogi II, skupaj s spremembami povzetka glavnih značilnosti zdravila in navodila za uporabo v Prilogi III.
Potential serious risks were identified during the decentralised procedure by two concerned Member States, Ireland and the United Kingdom, regarding the bioequivalence for the target species pigs. 
Med decentraliziranim postopkom sta dve zadevni državi članici, Irska in Združeno kraljestvo, opozorili na morebitna resna tveganja v zvezi z bioekvivalenco za ciljno vrsto prašiči.
Based on the evaluation of the currently available data, the CVMP considered that the particulars concerning the target species pigs that were submitted in support of the application do not comply with Article 13 of Directive 2001/82/EC, and consequently do not satisfy the criteria for authorisation in respect of safety and efficacy for the target species pigs. 
Odbor CVMP je na podlagi ocene trenutno razpoložljivih podatkov menil, da podatki o ciljni vrsti prašiči, ki so bili posredovani v podporo vlogi, niso skladni s členom 13 Direktive 2011/82/ES in posledično ne izpolnjujejo meril za odobritev, kar zadeva varnost in učinkovitost za ciljno vrsto prašiči.
The active substance is included in veterinary medicinal products currently authorised in the European Union via the centralised authorisation procedure, as well as nationally, for use in cattle, pigs, horses, dogs and cats. 
To zdravilno učinkovino vsebujejo zdravila za uporabo v veterinarski medicini, ki so trenutno v Evropski uniji odobrena tako po centraliziranem postopku pridobitve dovoljenja za promet kot po nacionalnih postopkih, in sicer za uporabo pri govedu, prašičih, konjih, psih in mačkah.
On 29 June 2012 the reference Member State, the Netherlands, notified to the European Medicines Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC. 
Referenčna država članica, Nizozemska, je 29. junija 2012 Evropsko agencijo za zdravila obvestila, da CMD(v) ni dosegla soglasja o zdravilu in da je v skladu s členom 33(4) Direktive 2001/82/ES zadevo napotila na odbor CVMP.
Therefore, the Committee adopted a negative opinion on 8 November 2012 recommending the refusal of the granting of the marketing authorisation for Melosolute 40 mg/ml solution for injection for the target species pigs. 
Odbor je zato 8. novembra 2012 sprejel negativno mnenje in priporočil zavrnitev vloge za izdajo dovoljenja za promet za zdravilo Melosolute 40 mg/ml raztopina za injiciranje za ciljno vrsto prašiči.
On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 2 May 2012. 
Ker ti pomisleki na 210. dan postopka še vedno niso bili rešeni, je bila zadeva 2. maja 2012 v skladu s členom 33(1) Direktive 2001/82/ES napotena na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirani postopek (zdravila za uporabo v veterinarski medicini) (CMD(v)).
Day 60 of the CMD(v) procedure was on 29 June 2012, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP. 
Na šestdeseti dan postopka CMD(v) dne 29. junija 2012 zadevne države članice niso dosegle soglasja o zdravilu, zato je bil postopek napoten na odbor CVMP.
This is a ‘hybrid' application according to Article 13(3) Directive 2001/82/EC, as amended, referring to the centrally authorised reference product Metacam 20 mg/ml solution for injection for cattle, pigs and horses (EU/2/97/004). 
Gre za hibridno vlogo v skladu s členom 13(3) Direktive 2001/82/ES, kakor je bila spremenjena, pri čemer je referenčno zdravilo, odobreno po centraliziranem postopku, zdravilo Metacam 20 mg/ml raztopina za injiciranje za govedo, prašiče in konje (EU/2/97/004).
The applicant, CP-Pharma Handelsgesellschaft mbH, submitted an application for a decentralised procedure for Melosolute 40 mg/ml solution for injection for cattle, pigs and horses. 
Predlagatelj, družba CP-Pharma Handelsgesellschaft mbH, je predložil vlogo za decentralizirani postopek za zdravilo Melosolute 40 mg/ml raztopina za injiciranje za govedo, prašiče in konje.
Melosolute 40 mg/ml solution for injection for cattle, pigs and horses contains meloxicam as active ingredient. 
Zdravilo Melosolute 40 mg/ml raztopina za injiciranje za govedo, prašiče in konje vsebuje zdravilno učinkovino meloksikam.
Opinion following an Article 33(4)0F referral for Melosolute 40 mg/ml solution for injection for cattle, pigs and horses 
Mnenje v zvezi z napotitvijo v skladu s členom 33(4)0F za zdravilo Melosolute 40 mg/ml raztopina za injiciranje za govedo, prašiče in konje
referral for Melosolute 40 mg/ml solution for injection for cattle, pigs and horses 
za zdravilo Melosolute 40 mg/ml raztopina za injiciranje za govedo, prašiče in konje
Alar Irs (Estonia) 
Alar Irs (Estonija)
Pieter de Graeff (The Netherlands) 
Pieter de Graeff (Nizozemska)
‘Essential' means that the hypertension has no obvious cause. 
„Esencialna“ pomeni, da hipertenzija nima očitnega vzroka.
The areas harmonised include: 
Usklajena so bila naslednja področja:
The companies that market these medicines are AstraZeneca and Takeda. 
Družbi, ki dajeta ta zdravila v promet, sta AstraZeneca in Takeda.
Why was Atacand Plus reviewed? 
Zakaj je bilo zdravilo Atacand Plus pregledano?
Atacand Plus is authorised in the EU via national procedures. 
Zdravilo Atacand Plus je v EU odobreno z nacionalnimi postopki.
Dose titration is recommended. 
Priporoča se titracija odmerka.
Atacand Plus is also available in the EU under other trade names: Atacand Plus Forte, Atacand Plus Mite, Atacand Zid, Blopresid, Blopress, Blopress Comp, Blopress Forte, Blopress Plus, CoKenzen, Hytacand, Parapres Comp, Parapres Comp Forte, Parapres Plus and Ratacand Plus. 
Zdravilo Atacand Plus je na voljo v EU tudi pod drugimi imeni: Atacand Plus Forte, Atacand Plus Mite, Atacand Zid, Blopresid, Blopress, Blopress Comp, Blopress Forte, Blopress Plus, CoKenzen, Hytacand, Parapres Comp, Parapres Comp Forte, Parapres Plus in Ratacand Plus.
The European Commission issued a decision on 16 September 2010. 
Evropska komisija je odločbo izdala dne 16. septembra 2010.Poročevalec:
It is used to treat essential hypertension (high blood pressure). 
Uporablja se za zdravljenje esencialne hipertenzije (visokega krvnega tlaka).
The European Medicines Agency has completed a review of Atacand Plus and associated names. 
Evropska agencija za zdravila je zaključila pregled zdravila Atacand Plus in povezanih imen.
This means that the doctor should try different tablet strengths until the strength that adequately controls the patient's blood pressure is found. 
To pomeni, da mora zdravnik preskusiti tablete različne jakosti, dokler ne najde jakosti, ki ustrezno nadzoruje bolnikov krvni tlak.
The Committee also harmonised other sections of the SmPC including sections on special warnings, interactions with other medicines and pregnancy and lactation. 
Odbor je uskladil tudi druga poglavja povzetka glavnih značilnosti zdravila, vključno s poglavji o posebnih opozorilih, medsebojnem delovanju z drugimi zdravili ter nosečnostjo in dojenjem.
It must also not be given to women in their second or third trimesters of pregnancy or to patients with severe kidney or liver problems, cholestasis (problems with the elimination of bile), gout (a painful inflammation of the joints) and hypokalaemia (low blood potassium levels) or hypercalcaemia (high blood calcium levels). 
Prav tako se ne sme dajati ženskam v drugem ali tretjem tromesečju nosečnosti ali bolnikom s hudimi ledvičnimi ali jetrnimi težavami, holestazo (težavami z izločanjem žolča), protinom (bolečim vnetjem sklepov) in hipokaliemijo (nizko koncentracijo kalija v krvi) ali hiperkalciemijo (visoko koncentracijo kalcija v krvi).
24 June 2010 
24. junija 2010
It works by increasing urine output, reducing the amount of fluid in the blood and reducing blood pressure. 
Deluje s povečanjem izločanja seča, zmanjšanjem količine tekočine v krvi in znižanjem krvnega tlaka.
The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone. 
Kombinacija obeh zdravilnih učinkovin ima aditiven učinek, kar pomeni, da zmanjšuje krvni tlak bolj kot vsako posamezno zdravilo.
Candesartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. 
Kandesartan je „antagonist receptorja za angiotenzin II“, kar pomeni, da zavira delovanje hormona angiotenzin II v telesu.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Atacand Plus in the European Union (EU). 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je treba v Evropski uniji (EU) uskladiti podatke o predpisovanju zdravila Atacand Plus.
Atacand Plus must not be used in patients who are hypersensitive (allergic) to the active substances, any of the other ingredients or to substances derived from sulfonamide. 
Zdravilo Atacand Plus se ne sme uporabljati pri bolnikih, ki so preobčutljivi za (alergični na) zdravilni učinkovini, katero koli drugo sestavino ali snov, izpeljano iz sulfonamida.
Atacand Plus should be taken at a dose of one tablet once a day. 
Odmerek zdravila Atacand Plus je ena tableta na dan.
Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). 
Angiotenzin II je močan vazokonstriktor (snov, ki oži krvne žile).
Atacand Plus is a medicine that contains two active substances candesartan cilexetil and hydrochlorothiazide. 
Atacand Plus je zdravilo, ki vsebuje zdravilni učinkovini kandesartan cileksetil in hidroklorotiazid.
This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed. 
To je v različnih državah članicah, kjer je zdravilo v prometu, privedlo do razhajanj glede uporabe zdravila, kot je razvidno iz povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo.
By blocking the receptors to which angiotensin II normally attaches, candesartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to fall. 
Kandesartan blokira receptorje, na katere se angiotenzin II običajno veže, s čimer preprečuje učinek hormona ter omogoča širjenje krvnih žil in zmanjšuje krvni tlak.